Article Text

other Versions

PDF
Serum and tissue prolactin levels in canine mammary tumours including inflammatory mammary carcinomas: insights into clinical and prognostic implications
  1. F. L. Queiroga, DVM, MSc, PhD1,2,3,
  2. M. D. Pérez-Alenza, DVM, PhD4,
  3. A. González Gil, DVM, PhD5,
  4. G. Silvan, DVM, PhD5,
  5. L. Peña, DVM, PhD4 and
  6. J. C. Illera, DVM, PhD5
  1. 1Department of Veterinary Sciences, Universidade de Trás-os-Montes e Alto Douro, Quinta dos Prados, UTAD, Vila Real 5001-801, Portugal
  2. 2Center for the Study of Animal Sciences, CECA-ICETA, University of Porto, Portugal
  3. 3Center for Research and Technology of Agro-Environment and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro, Vila Real 5001-801, Portugal
  4. 4Department of Animal Medicine, Surgery and Pathology, Facultad de Veterinaria, Universidad Complutense de Madrid, Ciudad Universitaria s/n, Madrid 28040, Spain
  5. 5Department of Animal Physiology, Facultad de Veterinaria, Universidad Complutense de Madrid, Ciudad Universitaria s/n, Madrid 28040, Spain
  1. E-mail for correspondence: fqueirog{at}utad.pt

Abstract

The biological implications of serum and tissue prolactin levels in canine mammary tumours (CMT) have been previously described although the influence of this hormone on inflammatory mammary carcinomas as well as its value as prognostic indicator remains to be properly clarified. Prolactin determinations were carried out by enzyme immunoassay in tumour tissue and serum of 39 female dogs with spontaneous CMT and in normal mammary gland and serum of 10 controls. Prolactin levels were higher in the case of CMT compared to controls (P<0.05). In malignant CMT, higher levels of tissue prolactin were associated with the occurrence of tumour relapse and/or distant metastasis (P<0.05). Inflammatory mammary carcinomas presented the highest values for tissue prolactin concentrations with concentrations significantly higher than other malignant non-inflammatory mammary carcinoma tumours (P<0.05). The high levels of prolactin found in cases with poor clinical prognoses, including inflammatory mammary carcinoma, open the possibility of being able to better stratify clinical cases in malignant CMT with a view to tailoring treatment appropriately.

  • Accepted July 13, 2014.

Statistics from Altmetric.com

  • Accepted July 13, 2014.
View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.